[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJapZWg3_kqtBJrqt4jGNYbd1jY1ywIA9PNKYoanx5Hw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Changi General Hospital",[4],100,false,17,5,269707,1,83,[14,16,18,21,24,26,28,30],{"name":15,"count":9},"Primary Aldosteronism",{"name":17,"count":9},"Primary Aldosteronism Due to Aldosterone Producing Adenoma",{"name":19,"count":20},"Stroke",4,{"name":22,"count":23},"Hypertension",3,{"name":25,"count":23},"Sexual Dysfunction",{"name":27,"count":23},"Endothelial Dysfunction",{"name":29,"count":23},"Quality of Life",{"name":31,"count":23},"Inflammation",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06100367","11C-Metomidate PET\u002FCT for Endocrine Hypertension and Characterisation of Adrenal Tumours","2025-05-25","11C-Metomidate PET\u002FCT imaging at Clinical Imaging Research Centre",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,69,96,114,142,160,178,206,224,242,260,287,305,323,348,376,403,427,452,476,511,537,568,592,619],{"intervention":37,"totalTrials":11,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":65,"NA":67},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[],{"trials":56,"activeCount":11,"soonestReadout":36},[57],{"nctId":34,"briefTitle":35,"status":58,"phases":59,"primaryCompletion":36,"completion":60,"start":61,"enrollment":6,"conditions":62,"interventions":64},"ACTIVE_NOT_RECRUITING",[41,42],"2025-12-31","2019-12-30",[17,15,63],"Adrenal Tumors",[37],{"trials":66,"activeCount":50},[],{"trials":68,"activeCount":50},[],{"intervention":70,"totalTrials":11,"cells":71},"Colonic lavage with polyethylene glycol",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":94},{"trials":73,"activeCount":50},[],{"trials":75,"activeCount":50},[],{"trials":77,"activeCount":50},[],{"trials":79,"activeCount":50},[],{"trials":81,"activeCount":50},[82],{"nctId":83,"briefTitle":84,"status":85,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"NCT05083572","Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers","UNKNOWN",[43],"2022-11-30","2021-03-10",32,[91],"Dysbiosis",[70,93],"Antibiotic",{"trials":95,"activeCount":50},[],{"intervention":93,"totalTrials":11,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":112},{"trials":99,"activeCount":50},[],{"trials":101,"activeCount":50},[],{"trials":103,"activeCount":50},[],{"trials":105,"activeCount":50},[],{"trials":107,"activeCount":50},[108],{"nctId":83,"briefTitle":84,"status":85,"phases":109,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":110,"interventions":111},[43],[91],[70,93],{"trials":113,"activeCount":50},[],{"intervention":115,"totalTrials":11,"cells":116},"10 day triple therapy",{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":140},{"trials":118,"activeCount":50},[],{"trials":120,"activeCount":50},[],{"trials":122,"activeCount":50},[],{"trials":124,"activeCount":50},[],{"trials":126,"activeCount":50},[127],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT02092506","RCT: Triple vs Sequential vs Concomitant Therapy H Pylori","COMPLETED",[43],"2014-06","2011-12",462,[136],"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)",[115,138,139],"10 day sequential therapy","10 day concomitant therapy",{"trials":141,"activeCount":50},[],{"intervention":138,"totalTrials":11,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":158},{"trials":145,"activeCount":50},[],{"trials":147,"activeCount":50},[],{"trials":149,"activeCount":50},[],{"trials":151,"activeCount":50},[],{"trials":153,"activeCount":50},[154],{"nctId":128,"briefTitle":129,"status":130,"phases":155,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":156,"interventions":157},[43],[136],[115,138,139],{"trials":159,"activeCount":50},[],{"intervention":139,"totalTrials":11,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":50},[],{"trials":165,"activeCount":50},[],{"trials":167,"activeCount":50},[],{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[172],{"nctId":128,"briefTitle":129,"status":130,"phases":173,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":174,"interventions":175},[43],[136],[115,138,139],{"trials":177,"activeCount":50},[],{"intervention":179,"totalTrials":11,"cells":180},"Omeprazole 20mg",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":204},{"trials":182,"activeCount":50},[],{"trials":184,"activeCount":50},[],{"trials":186,"activeCount":50},[],{"trials":188,"activeCount":50},[],{"trials":190,"activeCount":50},[191],{"nctId":192,"briefTitle":193,"status":85,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT03908619","A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis",[43],"2021-03-31","2019-04-16",252,[199],"Helicobacter Pylori Infection",[179,201,202,203],"Esomeprazole 20mg","Rabeprazole Sodium 20mg","Vonoprazan",{"trials":205,"activeCount":50},[],{"intervention":201,"totalTrials":11,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":222},{"trials":209,"activeCount":50},[],{"trials":211,"activeCount":50},[],{"trials":213,"activeCount":50},[],{"trials":215,"activeCount":50},[],{"trials":217,"activeCount":50},[218],{"nctId":192,"briefTitle":193,"status":85,"phases":219,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":220,"interventions":221},[43],[199],[179,201,202,203],{"trials":223,"activeCount":50},[],{"intervention":202,"totalTrials":11,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":240},{"trials":227,"activeCount":50},[],{"trials":229,"activeCount":50},[],{"trials":231,"activeCount":50},[],{"trials":233,"activeCount":50},[],{"trials":235,"activeCount":50},[236],{"nctId":192,"briefTitle":193,"status":85,"phases":237,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":238,"interventions":239},[43],[199],[179,201,202,203],{"trials":241,"activeCount":50},[],{"intervention":203,"totalTrials":11,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":258},{"trials":245,"activeCount":50},[],{"trials":247,"activeCount":50},[],{"trials":249,"activeCount":50},[],{"trials":251,"activeCount":50},[],{"trials":253,"activeCount":50},[254],{"nctId":192,"briefTitle":193,"status":85,"phases":255,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":256,"interventions":257},[43],[199],[179,201,202,203],{"trials":259,"activeCount":50},[],{"intervention":261,"totalTrials":11,"cells":262},"0.5 MAC desflurane",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":285},{"trials":264,"activeCount":50},[],{"trials":266,"activeCount":50},[],{"trials":268,"activeCount":50},[],{"trials":270,"activeCount":50},[],{"trials":272,"activeCount":50},[273],{"nctId":274,"briefTitle":275,"status":130,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT04717102","Evaluating the Use of 0.5 and 0.75 MAC Desflurane in Patients Undergoing Spinal Surgery",[43],"2024-03-27","2021-04-14",34,[281],"Anesthesia",[261,283,284],"0.75 MAC desflurane","1.0 MAC desflurane",{"trials":286,"activeCount":50},[],{"intervention":283,"totalTrials":11,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":50},[],{"trials":292,"activeCount":50},[],{"trials":294,"activeCount":50},[],{"trials":296,"activeCount":50},[],{"trials":298,"activeCount":50},[299],{"nctId":274,"briefTitle":275,"status":130,"phases":300,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":301,"interventions":302},[43],[281],[261,283,284],{"trials":304,"activeCount":50},[],{"intervention":284,"totalTrials":11,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":50},[],{"trials":310,"activeCount":50},[],{"trials":312,"activeCount":50},[],{"trials":314,"activeCount":50},[],{"trials":316,"activeCount":50},[317],{"nctId":274,"briefTitle":275,"status":130,"phases":318,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":319,"interventions":320},[43],[281],[261,283,284],{"trials":322,"activeCount":50},[],{"intervention":324,"totalTrials":11,"cells":325},"Simethicone",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":344,"NA":346},{"trials":327,"activeCount":50},[],{"trials":329,"activeCount":50},[],{"trials":331,"activeCount":50},[],{"trials":333,"activeCount":50},[334],{"nctId":335,"briefTitle":336,"status":130,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT02555228","Small Volume Simethicone Before Gastroscopy: Any Benefit?",[41,42],"2015-11","2015-08",54,[342],"Lesion of Stomach",[324],{"trials":345,"activeCount":50},[],{"trials":347,"activeCount":50},[],{"intervention":349,"totalTrials":11,"cells":350},"Liraglutide",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":372,"NA":374},{"trials":352,"activeCount":50},[],{"trials":354,"activeCount":50},[],{"trials":356,"activeCount":50},[],{"trials":358,"activeCount":50},[359],{"nctId":360,"briefTitle":361,"status":85,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":371},"NCT02654665","Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",[42],"2017-12","2018-12","2014-03",36,[368,369,370],"Non-alcoholic Fatty Liver Disease (NAFLD)","Weight Loss","Non-alcoholic Steatohepatitis (NASH)",[349],{"trials":373,"activeCount":50},[],{"trials":375,"activeCount":50},[],{"intervention":377,"totalTrials":11,"cells":378},"Rifaximin",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":399,"NA":401},{"trials":380,"activeCount":50},[],{"trials":382,"activeCount":50},[],{"trials":384,"activeCount":50},[],{"trials":386,"activeCount":50},[387],{"nctId":388,"briefTitle":389,"status":390,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":398},"NCT04775329","Primary Prophylaxis for Spontaneous Bacterial Peritonitis","TERMINATED",[41,42],"2023-01-01","2020-11-01",2,[396,397],"Decompensated Cirrhosis","Small Bowel Bacterial Overgrowth Syndrome",[377],{"trials":400,"activeCount":50},[],{"trials":402,"activeCount":50},[],{"intervention":404,"totalTrials":11,"cells":405},"Vitamin D",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":407,"activeCount":50},[],{"trials":409,"activeCount":50},[],{"trials":411,"activeCount":50},[412],{"nctId":413,"briefTitle":414,"status":85,"phases":415,"primaryCompletion":416,"completion":416,"start":393,"enrollment":417,"conditions":418,"interventions":420},"NCT04578470","Benign Paroxysmal Positional Vertigo (BPPV) in Older Patients",[41],"2022-11-01",60,[419],"Benign Paroxysmal Positional Vertigo",[404],{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[],{"intervention":428,"totalTrials":11,"cells":429},"Raltegravir",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":431,"activeCount":50},[],{"trials":433,"activeCount":50},[434],{"nctId":435,"briefTitle":436,"status":130,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT01027182","Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers",[40],"2010-03","2009-12",6,[442],"Human Immunodeficiency Virus",[428],{"trials":445,"activeCount":50},[],{"trials":447,"activeCount":50},[],{"trials":449,"activeCount":50},[],{"trials":451,"activeCount":50},[],{"intervention":453,"totalTrials":11,"cells":454},"11C-Metomidate PET\u002FCT Scan",{"EARLY_PHASE1":455,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":456,"activeCount":50},[457],{"nctId":458,"briefTitle":459,"status":130,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":465},"NCT03990701","Primary Aldosteronism and Surgically Curable Forms in Hypertension Patients Using 11C-Metomidate",[39],"2021-03-30","2018-05-21",25,[15,17],[453],{"trials":467,"activeCount":50},[],{"trials":469,"activeCount":50},[],{"trials":471,"activeCount":50},[],{"trials":473,"activeCount":50},[],{"trials":475,"activeCount":50},[],{"intervention":477,"totalTrials":394,"cells":478},"Ropivacaine",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":480,"activeCount":50},[],{"trials":482,"activeCount":50},[],{"trials":484,"activeCount":50},[],{"trials":486,"activeCount":50},[],{"trials":488,"activeCount":50},[],{"trials":490,"activeCount":50},[491,502],{"nctId":492,"briefTitle":493,"status":85,"phases":494,"primaryCompletion":495,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT02033603","Adductor Canal Versus Femoral Nerve Block for Analgesia Post Total Knee Arthroscopy",[44],"2014-09","2014-12","2014-01",30,[500],"Knee Osteoarthritis",[477],{"nctId":503,"briefTitle":504,"status":130,"phases":505,"primaryCompletion":506,"completion":339,"start":507,"enrollment":498,"conditions":508,"interventions":510},"NCT02330302","Single Shot Fascia Iliaca Block vs Femoral Nerve Block for Analgesia for Surgical Fixation of Hip Fractures",[44],"2015-03","2014-08",[509],"Hip Fracture",[477,477],{"intervention":512,"totalTrials":11,"cells":513},"Mineralocorticoid Receptor Antagonists",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":515,"activeCount":50},[],{"trials":517,"activeCount":50},[],{"trials":519,"activeCount":50},[],{"trials":521,"activeCount":50},[],{"trials":523,"activeCount":50},[],{"trials":525,"activeCount":50},[526],{"nctId":527,"briefTitle":528,"status":130,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT03174847","Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism",[],"2019-10-20","2020-09-20","2017-02-20",57,[15,17,535],"Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)",[512],{"intervention":538,"totalTrials":11,"cells":539},"proton pump inhibitor use",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":541,"activeCount":50},[],{"trials":543,"activeCount":50},[],{"trials":545,"activeCount":50},[],{"trials":547,"activeCount":50},[],{"trials":549,"activeCount":50},[],{"trials":551,"activeCount":50},[552],{"nctId":553,"briefTitle":554,"status":130,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":567},"NCT04426994","Hypomagnesemia Associated With Proton-Pump Inhibitor Use",[],"2018-01-30","2019-09-30","2017-01-31",211672,[561,562,563,564,565,566],"Proton Pump Inhibitor Adverse Reaction","Hypomagnesemia","Arrhythmias, Cardiac","Seizures","Hypocalcemia","Hypokalemia",[538],{"intervention":569,"totalTrials":11,"cells":570},"Omeprazole",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":572,"activeCount":50},[],{"trials":574,"activeCount":50},[],{"trials":576,"activeCount":50},[],{"trials":578,"activeCount":50},[],{"trials":580,"activeCount":50},[],{"trials":582,"activeCount":50},[583],{"nctId":584,"briefTitle":585,"status":130,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":366,"conditions":589,"interventions":591},"NCT02893709","Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)",[44],"2016-07","2015-06",[590],"Gastroesophageal Reflux Disease",[569],{"intervention":593,"totalTrials":11,"cells":594},"Ropivacaine 0.5% 20ml",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":596,"activeCount":50},[],{"trials":598,"activeCount":50},[],{"trials":600,"activeCount":50},[],{"trials":602,"activeCount":50},[],{"trials":604,"activeCount":50},[],{"trials":606,"activeCount":50},[607],{"nctId":608,"briefTitle":609,"status":130,"phases":610,"primaryCompletion":611,"completion":611,"start":496,"enrollment":366,"conditions":612,"interventions":617},"NCT02331030","A Randomised Trial Comparing Supraclavicular Block vs Supraclavicular and Pecs II Block in Arteriovenous Grafting",[44],"2016-12",[613,614,615,616],"Arteriovenous Fistula","Arteriovenous Graft","Kidney Failure, Chronic","Renal Failure, End-stage",[593,618],"Ropivacaine 0.5% 10ml",{"intervention":618,"totalTrials":11,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":622,"activeCount":50},[],{"trials":624,"activeCount":50},[],{"trials":626,"activeCount":50},[],{"trials":628,"activeCount":50},[],{"trials":630,"activeCount":50},[],{"trials":632,"activeCount":50},[633],{"nctId":608,"briefTitle":609,"status":130,"phases":634,"primaryCompletion":611,"completion":611,"start":496,"enrollment":366,"conditions":635,"interventions":636},[44],[613,614,615,616],[593,618]]